Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk.

Ashkir Z. et al, (2025), European heart journal. Cardiovascular Imaging, 26, 218 - 228

Flow inefficiencies in non-obstructive HCM revealed by kinetic energy and hemodynamic forces on 4D-flow CMR

Pola K. et al, (2024), European Heart Journal - Imaging Methods and Practice, 2

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Maron MS. et al, (2024), The New England journal of medicine, 390, 1849 - 1861

Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy.

Maron MS. et al, (2024), Journal of the American College of Cardiology, 83, 2037 - 2048

Load More